Clinical Trial

Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC

Study acronym: GPC3
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
Phase 1/2 randomized, controlled, open-label trial of theranostic pair RYZ811 (diagnostic) and RYZ801 (therapeutic) to identify and treat subjects with GPC3+ unresectable hepatocellular carcinoma (HCC)
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-12-04; most recent amendment 2026-04-06.
Trial Details
NCT Number NCT06726161
Lead Sponsor RayzeBio, Inc.
Conditions Hepatocellular Carcinoma (HCC)
Enrollment 590 participants
Start Date 2025-09-05
Primary Completion 2030-06 (estimated)
Study Completion 2031-06 (estimated)
Updated on ClinicalTrials.gov 2026-04-13